Comirnaty COVID-19 vaccine: what US patients should know

Comirnaty is the mRNA COVID-19 vaccine from Pfizer and BioNTech with full FDA approval for adults and updated formulations for current variants. Here is how it works, who it is for, and where it fits in the US vaccine landscape.

Comirnaty is the brand name for the Pfizer-BioNTech mRNA COVID-19 vaccine that first received US emergency use authorization in late 2020 and later obtained full FDA approval for people 16 years and older on 08/23/2021 FDA, 08/23/2021. In 2023 the FDA authorized updated monovalent formulations targeting circulating Omicron-lineage variants for use in the United States FDA, 09/11/2023.

As of: 06/06/2026 | Reading time: approx. 9 minutes

By the AD HOC NEWS editorial team - specialized in product-focused market coverage.

At a Glance

• Product: Comirnaty
• Category: mRNA COVID-19 vaccine
• Brand/Manufacturer: Pfizer and BioNTech
• Primary Use Cases: Prevention of symptomatic COVID-19
• Availability: Widely available in the United States via pharmacies and clinics
• Core Markets: North America, Europe, and other global regions where approved

What Comirnaty Is and How It Works

Comirnaty is an mRNA-based vaccine that delivers genetic instructions for cells to produce a piece of the SARS-CoV-2 spike protein, prompting an immune response without using live virus CDC, 09/12/2023.

The vaccine is formulated as a lipid nanoparticle suspension, which protects the fragile mRNA and helps it enter human cells in the upper arm muscle after injection FDA, 01/31/2022. Once the mRNA is read, it is broken down and does not integrate into DNA, according to FDA product information FDA, 01/31/2022.

The original Comirnaty formulation targeted the ancestral strain of SARS-CoV-2, while later updated versions were designed to better match specific Omicron-lineage variants based on FDA and CDC recommendations FDA, 09/11/2023.

Why Comirnaty Matters for US Consumers and Industry

In the United States, Comirnaty has been one of the most widely used COVID-19 vaccines since its initial rollout to health care workers and high-risk groups in December 2020 CDC, 10/03/2023.

The vaccine is used to help reduce the risk of symptomatic COVID-19, severe disease, hospitalization, and related disruptions to work, school, and everyday life, as highlighted in CDC guidance for people in the United States CDC, 10/03/2023.

For US employers and health systems, vaccination campaigns that include Comirnaty support continuity of operations by helping protect health care staff, essential workers, and vulnerable populations, according to public health recommendations HHS, 09/22/2023.

Comirnaty in the US and Global Market

Comirnaty is supplied throughout the United States under contracts with federal and state agencies as well as through commercial distribution channels, including retail pharmacies, clinics, and physician offices HHS, 09/12/2023.

Globally, the Pfizer-BioNTech vaccine has been authorized or approved in many regions through health authorities such as the European Medicines Agency, which granted conditional marketing authorization in the EU in December 2020 EMA, 10/30/2023.

Comirnaty competes with mRNA and non-mRNA COVID-19 vaccines from other manufacturers, with choices influenced by national vaccination strategies, supply agreements, and regulatory guidance in each country CDC, 09/12/2023.

• mRNA platform delivering spike protein instructions
• Intramuscular injection, typically in the upper arm
• Updated formulations aligned with circulating variants
• Used in US pharmacies, clinics, and health systems
• Developed jointly by Pfizer and BioNTech

Frequently Asked Questions About Comirnaty

Who can receive Comirnaty in the United States?
Eligibility for Comirnaty and related Pfizer-BioNTech COVID-19 vaccine formulations depends on age, health status, and current CDC recommendations for staying up to date with vaccination CDC, 10/03/2023.

How is Comirnaty given and where can I get it?
The vaccine is given as an intramuscular injection, usually in the upper arm, and is offered at many US pharmacies, doctors' offices, health departments, and vaccination clinics following local supply and recommendations Vaccines.gov, 10/05/2023.

Is Comirnaty fully approved by the FDA?
The Pfizer-BioNTech COVID-19 vaccine under the name Comirnaty has full FDA approval for people 16 years and older, while certain updated formulations have emergency use authorization for additional age groups FDA, 08/23/2021.

Comirnaty is developed and marketed by Pfizer Inc. in partnership with BioNTech SE based on a collaboration agreement focused on mRNA-based COVID-19 vaccines and boosters.

Pfizer Inc. is listed on the New York Stock Exchange, and the associated ISIN for the issuer is US7170811035.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.